Emergent Biosolutions will move manufacturing of anthrax treatment to Baltimore - Technical.ly Baltimore

Sciences

Jul. 20, 2017 8:34 am

Emergent Biosolutions will move manufacturing of anthrax treatment to Baltimore

The life sciences company acquired the drug from GlaxoSmithKline.

Emergent Biosolutions' Bayview facility.

(Courtesy photo)

Emergent Biosolutions doubled the size of its manufacturing facility in Bayview earlier this year. With an acquisition deal announced Wednesday, the life sciences company now has plans for the primary product that will be made there.

The Gaithersburg-based multinational is set to purchase an anthrax treatment from pharmaceutical giant GlaxoSmithKline in a deal that could be worth up to $96 million.

EBS is purchasing raxibacumab, an FDA-approved drug that treats inhaled anthrax. It already has the attention of the U.S. government. The deal also includes a federal contract to manufacture the antidote for the U.S. National Stockpile, which the country keeps in case of emergency.

 

“We’ve concluded that this is the product of choice for the U.S. government,” Emergent Biosolutions CEO Daniel J. Abdun-Nabi said on a Wednesday afternoon conference call with investors. It’s an interesting move for a company that got lots of attention for developing an FDA-approved anthrax vaccine. Abdun-Nadi said he believes the two products are “complementary.”

The company plans to move manufacturing of the its newly-acquired vaccine to Baltimore in 2020. It will be the anchor product at the Bayview facility, where bulk manufacturing will take place. The 112,000 sq. ft. spot is one of three Centers for Innovation in Advanced Development and Manufacturing that the U.S. Health and Human Services Department has designated to call if quick vaccine production is needed.

EBS’ other Baltimore manufacturing facility in Carroll-Camden will handle the fill/finish process.

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Alliance Data Systems acquires ‘select’ tech assets of Baltimore-based Blispay

Xometry raises $50M, led by Owings Mills-based Greenspring Associates

Maryland’s ID Agent acquired by Kaseya

SPONSORED

Baltimore

Building a data acquisition system? Don’t make this mistake

Baltimore, MD 21201

14 West

Junior Database Administrator

Apply Now

Kite Pharma plans manufacturing facility in Frederick County

Hanover-based KeyW to be acquired by Jacobs Engineering Group in $815M deal

The acquisition deal for Columbia-based Osiris Therapeutics is now complete

SPONSORED

Baltimore

How SmartLogic accelerated these startups’ product growth trajectories

Baltimore

14 West

Senior Java Software Engineer

Apply Now
Baltimore, MD 21201

14 West

Senior Data Engineer

Apply Now
Baltimore, MD

SmartLogic

Product Designer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!